Medicine and Dentistry
Osteoporosis
85%
Dual-Energy X-Ray Absorptiometry
55%
Patient with Type 2 Diabetes
52%
Maturity Onset Diabetes of the Young
43%
Tibia
36%
Osteogenesis Imperfecta
36%
FRAX
29%
Bone Density
29%
Cohort Analysis
27%
Cardiovascular Disease
27%
Postmenopause
27%
Screening
26%
Fibrinolysis
21%
Bone Strength
21%
Bone Mass
20%
Prevalence
20%
Quantitative Computed Tomography
20%
Fragility Fracture
19%
Evaluation Study
19%
Insulin Aspart
19%
Roux-en-Y Gastric Bypass
18%
Gastric Bypass Surgery
18%
Rickets
18%
Hormone Substitution
18%
Substitution Therapy
18%
Randomized Controlled Trial
16%
Hip
14%
Placebo
14%
Plasminogen Activator Inhibitor-1
14%
Absorptiometry
13%
Rosiglitazone
13%
Bone Structure
13%
Distal Radius
13%
Bone Turnover
12%
Plasminogen Activator
12%
Sex Difference
12%
Body Mass Index
11%
Drug Therapy
11%
Coronary Computed Tomography Angiography
11%
Osteolysis
11%
Music Therapy
10%
Outpatient
10%
X Linked Hypophosphatemic Rickets
10%
Clinical Trial
10%
Medical Record
10%
Lumbar Spine
10%
Hip Fracture
10%
Body Weight
9%
Hypophosphatemic Rickets
9%
Short Acting Insulin
9%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
58%
Replacement Therapy
45%
Randomized Controlled Trial
38%
Hip Fracture
30%
Prevalence
28%
Osteogenesis Imperfecta
27%
Fragility Fracture
27%
Rosiglitazone
26%
Insulin Aspart
24%
NPH Insulin
22%
Comorbidity
21%
Metformin
21%
Randomized Clinical Trial
20%
Cohort Study
19%
Resistant Hypertension
18%
Spironolactone
18%
Fibulin
18%
Clinical Trial
14%
Pharmacotherapy
13%
Insulin Analog
13%
Adverse Event
12%
Metformin Plus Rosiglitazone
12%
Parathyroid hormone[1-34]
11%
Graves Disease
10%
Antithyroid Agent
10%
Cardiovascular Disease
10%
Hypothyroidism
10%
Hyperglycemia
9%
Hemoglobin A1c
9%
Primary Osteoporosis
9%
Sleep Disordered Breathing
9%
Insulin Glargine
9%
Insulin Degludec
9%
Population Study
9%
Patient Registry
9%
Prescription Medication
9%
Rickets
9%
Biochemical Marker
9%
Interleukin 1 Receptor Blocking Agent
9%
Cytokine
9%
Interleukin 6 Receptor
9%
Hashimoto Disease
9%
Osteoprotegerin
9%
Pioglitazone
9%
Prospective Cohort Study
9%
PPAR Agonist
9%
Glucocorticoid
9%
Balaglitazone
9%
Chemotherapy
9%
Nursing and Health Professions
Evaluation Study
28%
Orthopedic Software
27%
Bone Density
24%
Fragility Fracture
23%
Music Therapy
18%
Non Insulin Dependent Diabetes Mellitus
18%
Outpatient
16%
Bone Mass
15%
Hip Fracture
14%
Screening
14%
Drug Therapy
12%
Socioeconomic Status
12%
Dual Energy X Ray Absorptiometry
12%
Comorbidity
11%
Malignant Neoplasm
11%
Blood Pressure
10%
Fat Mass
10%
Coronary Artery Disease
9%
Bone Densitometer
9%
Patient Satisfaction
9%
Hormone Substitution
9%
Bone Strength
9%
Pulse Rate
9%
Quality of Life
9%
Nausea and Vomiting
9%
Outpatient Department
9%
Side Effect
9%
Pilot Study
9%
Insulin Dependent Diabetes Mellitus
9%
Cancer Therapy
9%
Clinical Outcome
9%
Systematic Review
9%
Meta Analysis
9%
Patient with Type 2 Diabetes
9%
Computer Assisted Tomography
9%
Substitution Therapy
9%
Glucose Tolerance
9%
Forearm Fracture
9%
Sex Diagnosis
9%
Plasminogen Activator
9%
Hepatic Encephalopathy
9%
Borderline State
9%
Hodgkin Disease
9%
Insulin Aspart
9%
Lymphoma
9%
Densitometer
9%
Sleep Disordered Breathing
9%
Coronary Artery Blood Flow
9%
Bariatric Surgery
9%
Tissue Plasminogen Activator
7%
